Mandell Lionel A
Department of Medicine, Division of Infectious Diseases, McMaster University , Hamilton, Ontario , Canada.
Postgrad Med. 2015 Aug;127(6):607-15. doi: 10.1080/00325481.2015.1074030.
Community-acquired pneumonia is still a significant cause of morbidity and mortality and is often misdiagnosed and inappropriately treated. Although it can be caused by a wide variety of micro-organisms, the pneumococcus, atypicals, such as Mycoplasma pneumoniae and Chlamydophila pneumoniae, Staphylococcus aureus and certain Gram-negative rods are the usual pathogens encountered. The site-of-care decision is critical in determining the site and type of care as well as the extent of diagnostic workup. Antimicrobial therapy should be started as soon as possible particularly in those requiring admission to hospital, but typically the physician does not know with any degree of certainty the identity of the etiologic pathogen. A number of national guidelines have been published to help the physician with this choice. The initial drug(s) can be modified if necessary if the pathogen and its antimicrobial susceptibility pattern becomes known. Adjunctive therapy such as pressors and fluid replacement are of value and macrolides appear to help as well, likely secondary to their immunomodulatory effects. Recent data also suggest a role for steroids.
社区获得性肺炎仍然是发病和死亡的重要原因,且常常被误诊和不恰当地治疗。虽然它可由多种微生物引起,但肺炎球菌、非典型病原体,如肺炎支原体和肺炎衣原体、金黄色葡萄球菌以及某些革兰氏阴性杆菌是常见的病原体。治疗地点的决策对于确定治疗地点和类型以及诊断检查的范围至关重要。抗菌治疗应尽快开始,特别是对于那些需要住院治疗的患者,但通常医生并不确切知道病原体的身份。已经发布了一些国家指南来帮助医生做出这一选择。如果病原体及其抗菌药敏模式已知,必要时可调整初始用药。诸如升压药和液体补充等辅助治疗是有价值的,大环内酯类药物似乎也有帮助,这可能继发于它们的免疫调节作用。最近的数据也表明类固醇有一定作用。